ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
BeOne Medicines Ltd. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $6.04B | $5.66B | $5.28B | $4.92B | $4.52B | $4.14B | $3.78B | $3.29B | $2.89B | $2.53B | $2.19B | $1.90B | 98.5% | +33.5% |
| Other revenue | – | – | – | – | $39.91M | $34.71M | $30.70M | $24.79M | $202.66M | $236.15M | $268.93M | $306.12M | – | – |
| Research and development service revenue | – | – | – | – | – | – | – | – | – | – | – | $92.18M | – | – |
| Other | – | – | – | – | – | – | – | – | – | – | – | $11.23M | – | – |
| Right to access intellectual property revenue | – | – | – | – | – | – | – | – | – | – | – | $130.72M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.32B | $3.10B | $2.88B | $2.64B | $2.39B | $2.17B | $1.96B | $1.65B | $1.54B | $1.32B | $1.13B | $970.51M | 54.1% | +38.9% |
| China | $1.83B | $1.75B | $1.68B | $1.64B | $1.57B | $1.49B | $1.41B | $1.32B | $1.23B | $1.17B | $1.10B | $1.04B | 29.8% | +16.1% |
| Europe - total revenue | $743.18M | $686.81M | $611.37M | $552.63M | $484.32M | $414.32M | $362.63M | $296.26M | $283.57M | $238.35M | $202.01M | $169.90M | 12.1% | +53.5% |
| Rest of world - total revenue | – | – | – | $149.15M | $120.06M | $97.77M | $78.81M | $50.07M | $37.75M | $34.44M | $26.60M | $47.05M | – | – |
From the segment and revenue-disaggregation notes of BeOne Medicines's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.